C14 Ceramide (d18:1/14:0)

A bioactive sphingolipid

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥175.00

140.00

- +
5mg

￥825.00

660.00

- +
10mg

￥1462.00

1170.00

- +
25mg

￥3200.00

2560.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

C14 Ceramide is an endogenous ceramide generated by ceramide synthase 6. [1] During nutrient-deprivation-induced necroptosis in MEF cells, C14 ceramide levels increase in a time-dependent manner. [2] C14 ceramide plasma levels were reduced in obese patients with or without diabetes following a 12-week supervised exercise training program, correlating positively with weight and fat loss and negatively with an increase in insulin sensitivity. [3] In contrast, plasma levels were higher in Parkinson's disease patients with dementia than those without dementia and higher levels were correlated with deficits in memory.[4]

Reference:
[1]. Grosch, S., Schiffmann, S., and Geisslinger, G. Chain length-specific properties of ceramides. Prog. Lipid Res. 51(1), 50-62 (2012).
[2]. Sundaram, K., Mather, A.R., Marimuthu, S., et al. Loss of neutral ceramidase protects cells from nutrient- and energy -deprivation-induced cell death. Biochem J. 473(6), 43-55 (2016).
[3]. Kasumov, T., Solomon, T.P., Hwang, C., et al. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity (Silver Spring) 23(7), 1414-1421 (2015).
[4]. Xing, Y., Tang, Y., Zhao, L., et al. Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson’s disease dementia. J. Neurol. Sci. 370, 82-87 (2016).